Research Paper Volume 15, Issue 16 pp 8155—8184
Identified RP2 as a prognostic biomarker for glioma, facilitating glioma pathogenesis mainly via regulating tumor immunity
Figure 4. Correlation between RP2 hypomethylation, and prognosis in GBM and LGG. (A, B) The visualization between the methylation level and the RP2 expression. (C, D) The Kaplan–Meier survival of the promoter methylation of RP2. (E, F) The distribution landscape of methylation probes.